 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| lonigutamab (VB421) / Pierre Fabre, ACELYRIN
Enrollment change, Trial completion date, Trial primary completion date: Efficacy and Safety of Lonigutamab in Subjects with Thyroid Eye Disease (TED) (clinicaltrials.gov) - Sep 26, 2024
P1/2, N=54, Recruiting, Sponsor: ACELYRIN Inc.
N=38 --> 54 | Trial completion date: Oct 2024 --> May 2025 | Trial primary completion date: Oct 2024 --> May 2025
- lonigutamab (VB421) / Pierre Fabre, ACELYRIN
A Phase 1/2 Proof of Concept Study of Subcutaneous Lonigutamab (Anti (South Level 1 Lobby: STATION 1) - Sep 24, 2024 - Abstract #AAO2024AAO_1296;
P1/2
Patients achieved clinical responses early that were maintained over the time points evaluated, including Week 12 off-treatment, supporting the potential for longer dosing intervals. Evidence from cohort 1 indicates that Loni was well tolerated and displayed clinical efficacy responses, which is further supported by cohort 2 data.
- | lonigutamab (VB421) / Pierre Fabre, ACELYRIN
Trial completion date, Trial primary completion date: Efficacy and Safety of Lonigutamab in Subjects with Thyroid Eye Disease (TED) (clinicaltrials.gov) - Mar 22, 2024
P1/2, N=38, Recruiting, Sponsor: ACELYRIN Inc.
Evidence from cohort 1 indicates that Loni was well tolerated and displayed clinical efficacy responses, which is further supported by cohort 2 data. Trial completion date: Feb 2024 --> Oct 2024 | Trial primary completion date: Feb 2024 --> Oct 2024
- lonigutamab (VB421) / Pierre Fabre, ACELYRIN
Phase classification: Efficacy and Safety of Lonigutamab in Subjects with Thyroid Eye Disease (TED) (clinicaltrials.gov) - Jun 18, 2023
P1/2, N=38, Recruiting, Sponsor: ACELYRIN Inc.
Trial completion date: Feb 2024 --> Oct 2024 | Trial primary completion date: Feb 2024 --> Oct 2024 Phase classification: P1b --> P1/2
- | lonigutamab (VB421) / Pierre Fabre, ACELYRIN
Trial primary completion date: Efficacy and Safety of Lonigutamab in Subjects with Thyroid Eye Disease (TED) (clinicaltrials.gov) - Apr 11, 2023
P1b, N=36, Recruiting, Sponsor: ACELYRIN Inc.
Phase classification: P1b --> P1/2 Trial primary completion date: Sep 2023 --> Jan 2024
- || lonigutamab (VB421) / Pierre Fabre, ACELYRIN
New P1 trial, New P1/2 trial: Efficacy and Safety of Lonigutamab in Subjects with Thyroid Eye Disease (TED) (clinicaltrials.gov) - Jan 13, 2023
P1b, N=36, Recruiting, Sponsor: ValenzaBio, Inc.